JP2017521375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521375A5 JP2017521375A5 JP2016569887A JP2016569887A JP2017521375A5 JP 2017521375 A5 JP2017521375 A5 JP 2017521375A5 JP 2016569887 A JP2016569887 A JP 2016569887A JP 2016569887 A JP2016569887 A JP 2016569887A JP 2017521375 A5 JP2017521375 A5 JP 2017521375A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- fluoro
- substituted
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001153 fluoro group Chemical group F* 0.000 claims 35
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 15
- 229920006395 saturated elastomer Polymers 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 13
- 229910052805 deuterium Inorganic materials 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 229910052760 oxygen Chemical group 0.000 claims 9
- 239000001301 oxygen Chemical group 0.000 claims 9
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 150000003457 sulfones Chemical class 0.000 claims 4
- -1 deuteriomethyl Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 claims 1
- BJFCUPZGDUWSBC-CYBMUJFWSA-N 1-(3-tert-butylsulfonyl-4-cyano-2-hydroxyphenyl)-3-[(1R)-2-methylcyclopent-2-en-1-yl]urea Chemical compound C(C)(C)(C)S(=O)(=O)C=1C(=C(C=CC1C#N)NC(=O)N[C@H]1C(=CCC1)C)O BJFCUPZGDUWSBC-CYBMUJFWSA-N 0.000 claims 1
- QFRNMJLWLBDGBM-CYBMUJFWSA-N 1-[(1R)-2-chlorocyclopent-2-en-1-yl]-3-[4-chloro-2-hydroxy-3-(4-methyloxan-4-yl)sulfonylphenyl]urea Chemical compound ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)Cl)O)S(=O)(=O)C1(CCOCC1)C QFRNMJLWLBDGBM-CYBMUJFWSA-N 0.000 claims 1
- XIABUGIQEBJFJU-SJKOYZFVSA-N 1-[(1R)-2-chlorocyclopent-2-en-1-yl]-3-[4-chloro-2-hydroxy-3-[(3R)-3-methyloxolan-3-yl]sulfonylphenyl]urea Chemical compound ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)Cl)O)S(=O)(=O)[C@]1(COCC1)C XIABUGIQEBJFJU-SJKOYZFVSA-N 0.000 claims 1
- XIABUGIQEBJFJU-PXAZEXFGSA-N 1-[(1R)-2-chlorocyclopent-2-en-1-yl]-3-[4-chloro-2-hydroxy-3-[(3S)-3-methyloxolan-3-yl]sulfonylphenyl]urea Chemical compound ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)Cl)O)S(=O)(=O)[C@@]1(COCC1)C XIABUGIQEBJFJU-PXAZEXFGSA-N 0.000 claims 1
- DNXKACKCTLURQN-FZKQIMNGSA-N 1-[4-chloro-2-hydroxy-3-[(3R)-3-methyloxolan-3-yl]sulfonylphenyl]-3-[(1R)-2-methylcyclopent-2-en-1-yl]urea Chemical compound ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)C)O)S(=O)(=O)[C@]1(COCC1)C DNXKACKCTLURQN-FZKQIMNGSA-N 0.000 claims 1
- YBYYXPLVAYECOJ-SNVBAGLBSA-N 1-[4-chloro-3-(1,1-difluoroethylsulfonyl)-2-hydroxyphenyl]-3-[(1R)-2-methylcyclopent-2-en-1-yl]urea Chemical compound ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)C)O)S(=O)(=O)C(C)(F)F YBYYXPLVAYECOJ-SNVBAGLBSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- UADSESNXJPFVMK-UMVBOHGHSA-N ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)C)O)S(=O)(=O)[C@@H]1C[C@H](C1)N(C)C Chemical compound ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)C)O)S(=O)(=O)[C@@H]1C[C@H](C1)N(C)C UADSESNXJPFVMK-UMVBOHGHSA-N 0.000 claims 1
- WBYPYLOMGPXCEJ-BFYDXBDKSA-N ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)C)O)S(=O)(=O)[C@@H]1C[C@H](C1)N1CCCC1 Chemical compound ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)C)O)S(=O)(=O)[C@@H]1C[C@H](C1)N1CCCC1 WBYPYLOMGPXCEJ-BFYDXBDKSA-N 0.000 claims 1
- DNXKACKCTLURQN-ACJLOTCBSA-N ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)C)O)S(=O)(=O)[C@@]1(COCC1)C Chemical compound ClC1=C(C(=C(C=C1)NC(=O)N[C@H]1C(=CCC1)C)O)S(=O)(=O)[C@@]1(COCC1)C DNXKACKCTLURQN-ACJLOTCBSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 0 *C(CC1)=C(*)C1NC(Nc1ccc(*)c(S(*)(=O)=O)c1O)=O Chemical compound *C(CC1)=C(*)C1NC(Nc1ccc(*)c(S(*)(=O)=O)c1O)=O 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/000545 | 2014-05-29 | ||
| CN2014000545 | 2014-05-29 | ||
| CN2014083380 | 2014-07-31 | ||
| CNPCT/CN2014/083380 | 2014-07-31 | ||
| CN2015077947 | 2015-04-30 | ||
| CNPCT/CN2015/077947 | 2015-04-30 | ||
| PCT/EP2015/061618 WO2015181186A1 (en) | 2014-05-29 | 2015-05-27 | 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521375A JP2017521375A (ja) | 2017-08-03 |
| JP2017521375A5 true JP2017521375A5 (enExample) | 2018-07-05 |
| JP6580598B2 JP6580598B2 (ja) | 2019-09-25 |
Family
ID=53276107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569887A Expired - Fee Related JP6580598B2 (ja) | 2014-05-29 | 2015-05-27 | Ｃｘｃｒ２阻害剤としての１−（シクロペント−２−エン−１−イル）−３−（２−ヒドロキシ−３−（アリールスルホニル）フェニル）尿素誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10106515B2 (enExample) |
| EP (1) | EP3148963B1 (enExample) |
| JP (1) | JP6580598B2 (enExample) |
| KR (1) | KR20170007481A (enExample) |
| CN (1) | CN107027306B (enExample) |
| AU (1) | AU2015265993B2 (enExample) |
| BR (1) | BR112016028037A2 (enExample) |
| CA (1) | CA2950466A1 (enExample) |
| CL (1) | CL2016003024A1 (enExample) |
| CR (1) | CR20160557A (enExample) |
| DO (1) | DOP2016000312A (enExample) |
| EA (1) | EA031477B1 (enExample) |
| ES (1) | ES2685595T3 (enExample) |
| IL (1) | IL248824A0 (enExample) |
| MX (1) | MX2016015642A (enExample) |
| PE (1) | PE20170083A1 (enExample) |
| PH (1) | PH12016502347A1 (enExample) |
| TW (1) | TW201609618A (enExample) |
| UY (1) | UY36141A (enExample) |
| WO (1) | WO2015181186A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377396B (es) | 2013-09-12 | 2025-03-10 | Janssen Biopharma Inc | Compuestos de azapiridona y usos de los mismos. |
| RU2017106172A (ru) * | 2014-07-31 | 2018-08-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) |
| PL3402474T3 (pl) * | 2016-01-15 | 2021-12-27 | Dompé Farmaceutici S.P.A. | Inhibitory il-8 do zastosowania w leczeniu wywołanej chemioterapią neuropatii obwodowej |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| US12577235B2 (en) | 2019-07-11 | 2026-03-17 | Shenzhen Optimum Biological Technology Co., Ltd | Crystalline form of CXCR2 antagonist and application thereof |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN113754613B (zh) * | 2021-09-27 | 2023-06-30 | 北京工商大学 | 一种4-烯醇的苯硫基环醚化方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5280089A1 (es) * | 2000-03-16 | 2003-05-30 | Smithkline Beecham Corp | Antagonistas del receptor il-8 |
| ATE552236T1 (de) * | 2003-01-14 | 2012-04-15 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz |
| EP1812008A4 (en) * | 2004-10-20 | 2008-10-29 | Smithkline Beecham Corp | ANTAGONISTS OF THE IL-8 RECEPTOR |
| PL2009992T3 (pl) | 2006-04-21 | 2012-11-30 | Glaxosmithkline Llc | Antagoniści receptora IL-8 |
| CA2656150A1 (en) * | 2006-06-28 | 2008-01-03 | Sanofi-Aventis | New cxcr2 inhibitors |
| CA2747637A1 (en) * | 2008-12-18 | 2010-07-15 | Janssen Pharmaceutica Nv | Sulfamides as trpm8 modulators |
| RU2017106172A (ru) | 2014-07-31 | 2018-08-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) |
-
2015
- 2015-05-08 CR CR20160557A patent/CR20160557A/es unknown
- 2015-05-27 JP JP2016569887A patent/JP6580598B2/ja not_active Expired - Fee Related
- 2015-05-27 EP EP15726090.2A patent/EP3148963B1/en active Active
- 2015-05-27 MX MX2016015642A patent/MX2016015642A/es unknown
- 2015-05-27 PE PE2016002269A patent/PE20170083A1/es not_active Application Discontinuation
- 2015-05-27 CN CN201580036634.5A patent/CN107027306B/zh not_active Expired - Fee Related
- 2015-05-27 KR KR1020167036322A patent/KR20170007481A/ko not_active Withdrawn
- 2015-05-27 US US15/314,124 patent/US10106515B2/en not_active Expired - Fee Related
- 2015-05-27 UY UY0001036141A patent/UY36141A/es not_active Application Discontinuation
- 2015-05-27 AU AU2015265993A patent/AU2015265993B2/en not_active Ceased
- 2015-05-27 ES ES15726090.2T patent/ES2685595T3/es active Active
- 2015-05-27 CA CA2950466A patent/CA2950466A1/en not_active Abandoned
- 2015-05-27 EA EA201692474A patent/EA031477B1/ru not_active IP Right Cessation
- 2015-05-27 TW TW104116922A patent/TW201609618A/zh unknown
- 2015-05-27 WO PCT/EP2015/061618 patent/WO2015181186A1/en not_active Ceased
- 2015-05-27 BR BR112016028037A patent/BR112016028037A2/pt not_active Application Discontinuation
-
2016
- 2016-11-08 IL IL248824A patent/IL248824A0/en unknown
- 2016-11-24 CL CL2016003024A patent/CL2016003024A1/es unknown
- 2016-11-25 PH PH12016502347A patent/PH12016502347A1/en unknown
- 2016-11-28 DO DO2016000312A patent/DOP2016000312A/es unknown
-
2018
- 2018-09-13 US US16/129,867 patent/US10336719B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521375A5 (enExample) | ||
| JP2013510125A5 (enExample) | ||
| JP2011529054A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2021523221A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2016522266A5 (enExample) | ||
| JP2019514874A5 (enExample) | ||
| FI3848027T3 (fi) | Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita | |
| CN109715626A (zh) | 作为fgfr抑制剂的杂环化合物 | |
| JP2014513110A5 (enExample) | ||
| JP2011519854A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| JP2019531279A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| JP2016506958A5 (enExample) | ||
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| JP2017508782A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2017522277A5 (enExample) | ||
| JP2017506666A5 (enExample) |